Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new ...

In keeping with our new Diabetes Canada Guidelines that all people with type 1 diabetes should use an AID System, the arrival of Omnipod 5 will be life changing for many people living with ...

Insulet also recently expanded sensor integrations to include Dexcom G7 for Omnipod 5 users in the U.K. and the Netherlands. Additionally, Insulet is planning to bring Omnipod 5 to five more markets ...

Presently, Omnipod 5 is FDA-cleared in the United States and C.E. marked for use in those with type 1 diabetes aged two years and older. The SECURE-T2D pivotal trial primarily aimed to evaluate ...

“Canadians living with type 1 diabetes have been anxiously awaiting the arrival of Omnipod 5, the only tubeless commercial AID System. In keeping with our new Diabetes Canada Guidelines that all ...

In August 2024, the FDA cleared Omnipod 5 for use by people with type 2 diabetes (18 years and above), expanding the technology to nearly six million insulin-requiring people in the United States.

Insulet Corporation (NASDAQ: PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with ...

He emphasized the strong demand and adoption of Omnipod 5 across both type 1 and type 2 diabetes segments, with over 500,000 global customers, including 365,000 active Omnipod 5 users. Omnipod 5 ...

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention ...